Natural history and disease progression of chronic hepatitis B virus infection.
- Author:
Lei Jie WANG
1
;
Ming Wei LI
2
;
Yan Na LIU
1
;
Xiang Mei CHEN
1
;
Jing Min ZHAO
3
;
Shu Hong LIU
3
;
Feng Min LU
1
Author Information
1. Department of Microbiology & Infectious Disease Center, Peking University School of Basic Medical Sciences, Beijing 100191, China.
2. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
3. Department of Pathology and Hepatology, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100039, China.
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Hepatitis B e antigen;
Natural history
- MeSH:
Adolescent;
Adult;
DNA, Viral;
Disease Progression;
Female;
Hepatitis B e Antigens;
Hepatitis B virus/genetics*;
Hepatitis B, Chronic/diagnosis*;
Humans;
Male;
Retrospective Studies;
Young Adult
- From:
Journal of Peking University(Health Sciences)
2022;54(5):920-926
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To better understand and revise the natural history and disease progression of chronic hepatitis B virus (HBV) infection through analysis of a single-center large-scale cohort of indivi-duals with chronic HBV infection.
METHODS:Patients with chronic HBV infection who had undergone liver biopsy in the Fifth Medical Center of Chinese People's Liberation Army (PLA) General Hospital from January 2014 to October 2020 were retrospectively recruited. Based on patient's hepatitis B e antigen (HBeAg) states and pathologic diagnosis, they were categorized into four disease progression statuses (or phases according to the old-terminology in the updated guidelines of chronic hepatitis B (CHB), such as European Association for the Study of the Liver (EASL) 2017, Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection: HBeAg-positive chronic HBV infection (immune tolerance), HBeAg-positive CHB (immune active HBeAg positive), HBeAg-negative chronic HBV infection (inactive carrier), and HBeAg-negative CHB (immune reactive HBeAg negative). Then the demographic, laboratory tests and liver histological results of the patients in different disease progression stages were compared. Age differences between the two groups were evaluated using Mann-Whitney U test.
RESULTS:A total of 760 eligible patients with a median age of 29 (interquartile range: 16-39) years were enrolled. Among them, 197 were underage individuals (age < 18 years) and 563 were adults; and 456 were males and 304 females. According to the pathological diagnosis, the patients were classified, and in each of the above four natural disease phases there were 173, 329, 95, and 163 individuals, respectively. Further comparison of the ages of the patients of the four disease progression statuses revealed that patients of HBeAg-negative CHB had a median age at 37 years, which was reasonably higher than those with HBeAg-positive CHB in immune active phase (37 vs. 24 years, P < 0.001), but was relatively younger than those with HBeAg-negative chronic HBV infection (37 vs. 39 years, P= 0.240).
CONCLUSION:According to this study, it could be speculated that HBeAg-negative CHB patients probably not all reactivate from individuals of HBeAg-negative chronic HBV infection. Instead, certain HBeAg-negative CHB patients may also come from HBeAg-positive CHB patients who have undergone HBeAg clearance or seroconversion and still remain in the immune active state.
